CoChat

Revisiting inconsistency in large pharmacogenomic studies

Open access
Safikhani, Zhaleh, Smirnov, Petr, Freeman, Mark, El-Hachem, Nehme, She, Adrian, Rene, Quevedo, Goldenberg, Anna, Birkbak, Nicolai J., Hatzis, Christos, Shi, Leming, Beck, Andrew H., Aerts, Hugo J.W.L., Quackenbush, John, Haibe-Kains, Benjamin · 2016 · F1000Research
Cited by 96

The DOI matches its Crossref record.

Abstract

In 2013, we published a comparative analysis mutation and gene expression profiles and drug sensitivity measurements for 15 drugs characterized in the 471 cancer cell lines screened in the Genomics of Drug Sensitivity in Cancer (GDSC) and Cancer Cell Line Encyclopedia (CCLE). While we found good concordance in gene expression profiles, there was substantial inconsistency in the drug responses reported by the GDSC and CCLE projects. We received extensive feedback on the comparisons that we performed. This feedback, along with the release of new data, prompted us to revisit our initial analysis. Here we present a new analysis using these expanded data in which we address the most significant suggestions for improvements on our published analysis — that targeted therapies and broad cytotoxic drugs should have been treated differently in assessing consistency, that consistency of both molecular profiles and drug sensitivity measurements should both be compared across cell lines, and that the software analysis tools we provided should have been easier to run, particularly as the GDSC and CCLE released additional data. Our re-analysis supports our previous finding that gene expression data are significantly more consistent than drug sensitivity measurements. The use of new statistics to assess data consistency allowed us to identify two broad effect drugs and three targeted drugs with moderate to good consistency in drug sensitivity data between GDSC and CCLE. For three other targeted drugs, there were not enough sensitive cell lines to assess the consistency of the pharmacological profiles. We found evidence of inconsistencies in pharmacological phenotypes for the remaining eight drugs. Overall, our findings suggest that the drug sensitivity data in GDSC and CCLE continue to present challenges for robust biomarker discovery. This re-analysis provides additional support for the argument that experimental standardization and validation of pharmacogenomic response will be necessary to advance the broad use of large pharmacogenomic screens.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.12688/f1000research.9611.1

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 33

  1. M Garnett, 2012, Systematic identification of genomic markers of drug sensitivity in cancer cells., Nature., 483, 570-5, 10.1038/nature11005 · DOI · Paper page
  2. J Barretina, 2012, The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity., Nature., 483, 603-7, 10.1038/nature11003 · DOI · Paper page
  3. S Papillon-Cavanagh, 2013, Comparison and validation of genomic predictors for anticancer drug sensitivity., J Am Med Inform Assoc., 20, 597-602, 10.1136/amiajnl-2012-001442 · DOI · Paper page
  4. Z Dong, 2015, Anticancer drug sensitivity prediction in cell lines from baseline gene expression through recursive feature selection., BMC Cancer., 15, 489, 10.1186/s12885-015-1492-6 · DOI
  5. I Jang, 2014, Systematic assessment of analytical methods for drug sensitivity prediction from cancer cell line data., Pac Symp Biocomput., 63-74, 10.1142/9789814583220_0007 · DOI · Paper page
  6. I Cortés-Ciriano, 2016, Improved large-scale prediction of growth inhibition patterns using the NCI60 cancer cell line panel., Bioinformatics., 32, 85-95, 10.1093/bioinformatics/btv529 · DOI · Paper page
  7. B Haibe-Kains, 2013, Inconsistency in large pharmacogenomic studies., Nature., 504, 389-93, 10.1038/nature12831 · DOI · Paper page
  8. C Hatzis, 2014, Enhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward?, Cancer Res., 74, 4016-23, 10.1158/0008-5472.CAN-14-0725 · DOI · Paper page
  9. Z Safikhani, 2016, Assessment of pharmacogenomic agreement [version 1; referees: 3 approved]., F1000 Res., 5, 825, 10.12688/f1000research.8705.1 · DOI
  10. P Haverty, 2016, Reproducible pharmacogenomic profiling of cancer cell line panels., Nature., 533, 333-7, 10.1038/nature17987 · DOI · Paper page
  11. P Smirnov, 2016, PharmacoGx: an R package for analysis of large pharmacogenomic datasets., Bioinformatics., 32, 1244-6, 10.1093/bioinformatics/btv723 · DOI · Paper page
  12. H Hong, 2012, Technical reproducibility of genotyping SNP arrays used in genome-wide association studies., PLoS One., 7, e44483, 10.1371/journal.pone.0044483 · DOI
  13. M Yu, 2015, A resource for cell line authentication, annotation and quality control., Nature., 520, 307-11, 10.1038/nature14397 · DOI · Paper page
  14. A Goodspeed, 2015, Tumor-derived Cell Lines as Molecular Models of Cancer Pharmacogenomics., Mol Cancer Res., 14, 3-13, 10.1158/1541-7786.MCR-15-0189 · DOI · Paper page
  15. 2015, Pharmacogenomic agreement between two cancer cell line data sets., Nature., 528, 84-7, 10.1038/nature15736 · DOI · Paper page
  16. W Youden, 1950, Index for rating diagnostic tests., Cancer., 3, 32-5, 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3 · doi:10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3
  17. K Pearson, 1895, Note on Regression and Inheritance in the Case of Two Parents., Proc R Soc Lond., 58, 240-2
  18. C Spearman, 1987, The proof and measurement of association between two things. By C. Spearman, 1904., Am J Psychol., 100, 441-71
  19. R Somers, 1962, A New Asymmetric Measure of Association for Ordinal Variables., Am Sociol Rev., 27, 799-811, 10.2307/2090408 · DOI · Paper page
  20. B Matthews, 1975, Comparison of the predicted and observed secondary structure of T4 phage lysozyme., Biochim Biophys Acta., 405, 442-51, 10.1016/0005-2795(75)90109-9 · DOI · Paper page
  21. A Hudson, 2014, Discrepancies in cancer genomic sequencing highlight opportunities for driver mutation discovery., Cancer Res., 74, 6390-6, 10.1158/0008-5472.CAN-14-1020 · DOI
  22. F Harrell, 1982, Evaluating the yield of medical tests., JAMA., 247, 2543-6, 10.1001/jama.1982.03320430047030 · DOI · Paper page
  23. L MAQC Consortium, Shi, 2006, The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements., Nat Biotechnol., 24, 1151-61, 10.1038/nbt1239 · DOI · Paper page
  24. L Shi, 2010, The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models., Nat Biotechnol., 28, 827-38, 10.1038/nbt.1665 · DOI · Paper page
  25. N Pozdeyev, 2016, Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies., Oncotarget., 7, 51619-51625, 10.18632/oncotarget.10010 · DOI
  26. R Irizarry, 2003, Exploration, normalization, and summaries of high density oligonucleotide array probe level data., Biostatistics., 4, 249-64, 10.1093/biostatistics/4.2.249 · DOI · Paper page
  27. W de Leeuw, 2008, Salvaging Affymetrix probes after probe-level re-annotation., BMC Res Notes., 1, 66, 10.1186/1756-0500-1-66 · DOI
  28. S Carter, 2012, Absolute quantification of somatic DNA alterations in human cancer., Nat Biotechnol., 30, 413-21, 10.1038/nbt.2203 · DOI · Paper page
  29. C Wilks, 2014, The Cancer Genomics Hub (CGHub): overcoming cancer through the power of torrential data., Database (Oxford)., 2014, 10.1093/database/bau093 · DOI · Paper page
  30. C Trapnell, 2012, Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks., Nat Protoc., 7, 562-78, 10.1038/nprot.2012.016 · DOI · Paper page
  31. A Bairoch, 2015, ExPASy - Cellosaurus [Internet]., Cellosaurus.
  32. Y Benjamini, 1995, Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing., J R Stat Soc Series B Stat Methodol., 57, 289-300, 10.1111/j.2517-6161.1995.tb02031.x · DOI · Paper page
  33. Z Safikhani, 2016, Dataset: Revisiting inconsistency in large pharmacogenomics studies., Open Science Framework.

Cited by

See all 96

Metadata

Authors
Safikhani, Z., Smirnov, P., Freeman, M., El-Hachem, N., She, A., Rene, Q., Goldenberg, A., Birkbak, N. J., Hatzis, C., Shi, L., Beck, A. H., Aerts, H. J. W. L., Quackenbush, J., & Haibe-Kains, B.
Venue
F1000Research
Published
2016-09-16
Volume
5
Pages
2333
ISSN
2046-1402 (ISSN-L)
OpenAlex
W4234509242
Cited by
96
References
0
FWCI
9.82
Type
journal article
Language
en
Open access
gold
Licence
creativecommons.org/licenses/by/4.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Revisiting inconsistency in large pharmacogenomic studies. https://app.cochat.ai/papers/10.12688/f1000research.9611.1
The paper
Safikhani, Z., Smirnov, P., Freeman, M., El-Hachem, N., She, A., Rene, Q., Goldenberg, A., Birkbak, N. J., Hatzis, C., Shi, L., Beck, A. H., Aerts, H. J. W. L., Quackenbush, J., & Haibe-Kains, B. (2016). Revisiting inconsistency in large pharmacogenomic studies. F1000Research. https://doi.org/10.12688/f1000research.9611.1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.